ILiAD Biotechnologies Revenue and Competitors
Estimated Revenue & Valuation
- ILiAD Biotechnologies's estimated annual revenue is currently $2.2M per year.
- ILiAD Biotechnologies's estimated revenue per employee is $77,500
Employee Data
- ILiAD Biotechnologies has 29 Employees.
- ILiAD Biotechnologies grew their employee count by 12% last year.
ILiAD Biotechnologies's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder and CEO | Reveal Email/Phone |
2 | Chief Operating Officer | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Chief Operating Officer | Reveal Email/Phone |
5 | Executive Director | Reveal Email/Phone |
6 | General Manager International Operations | Reveal Email/Phone |
7 | Controller | Reveal Email/Phone |
8 | Administrative Specialist | Reveal Email/Phone |
ILiAD Biotechnologies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $17.5M | 113 | 14% | N/A | N/A |
#2 | $1.9M | 12 | 0% | N/A | N/A |
#3 | $1.1M | 7 | 0% | N/A | N/A |
#4 | $4.5M | 29 | 21% | N/A | N/A |
#5 | $4.8M | 31 | 11% | N/A | N/A |
#6 | $3.1M | 20 | N/A | N/A | N/A |
#7 | $0.8M | 5 | 0% | N/A | N/A |
#8 | $1.1M | 7 | 0% | N/A | N/A |
#9 | $2.6M | 17 | 6% | N/A | N/A |
#10 | $0.6M | 4 | -56% | N/A | N/A |
What Is ILiAD Biotechnologies?
ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.
keywords:N/AN/A
Total Funding
29
Number of Employees
$2.2M
Revenue (est)
12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.5M | 30 | 0% | N/A |
#2 | N/A | 31 | 19% | N/A |
#3 | $3.7M | 31 | 0% | N/A |
#4 | $8.1M | 31 | -9% | N/A |
#5 | $1.7M | 32 | -30% | N/A |